Absci Collaborates with Global Cancer Center to Discover Novel Therapeutics Using Generative AI
Absci (Nasdaq: ABSI) has announced a collaboration with Memorial Sloan Kettering Cancer Center (MSK) to discover and develop up to six novel cancer therapeutics using generative AI. This partnership combines Absci's Integrated Drug Creation™ platform with MSK's renowned cancer research expertise. The collaboration aims to advance cancer research and develop new therapies for patients.
This initiative adds to Absci's growing list of research and drug development collaborations, including partnerships with AstraZeneca, Almirall, Merck, and NVIDIA. Absci is also developing its own pipeline of drug candidates, such as ABS-101, a potential best-in-class anti-TL1A antibody designed using generative AI.
Absci (Nasdaq: ABSI) ha annunciato una collaborazione con il Memorial Sloan Kettering Cancer Center (MSK) per scoprire e sviluppare fino a sei nuovi terapeutici per il cancro utilizzando l'IA generativa. Questa partnership combina la piattaforma Integrated Drug Creation™ di Absci con la rinomata esperienza di ricerca sul cancro di MSK. L'obiettivo della collaborazione è avanzare nella ricerca sul cancro e sviluppare nuove terapie per i pazienti.
Questa iniziativa si aggiunge alla crescente lista di collaborazioni di ricerca e sviluppo di farmaci di Absci, tra cui alleanze con AstraZeneca, Almirall, Merck e NVIDIA. Absci sta anche sviluppando il proprio portafoglio di candidati farmaci, come ABS-101, un potenziale anticorpo anti-TL1A di classe superiore progettato con l'IA generativa.
Absci (Nasdaq: ABSI) ha anunciado una colaboración con el Memorial Sloan Kettering Cancer Center (MSK) para descubrir y desarrollar hasta seis nuevos tratamientos contra el cáncer utilizando IA generativa. Esta asociación combina la plataforma Integrated Drug Creation™ de Absci con la reconocida experiencia en investigación del cáncer de MSK. El objetivo de la colaboración es avanzar en la investigación sobre el cáncer y desarrollar nuevas terapias para los pacientes.
Esta iniciativa se suma a la creciente lista de colaboraciones en investigación y desarrollo de fármacos de Absci, que incluye asociaciones con AstraZeneca, Almirall, Merck y NVIDIA. Absci también está desarrollando su propio portafolio de candidatos a fármacos, como ABS-101, un anticuerpo anti-TL1A potencialmente de primera categoría diseñado con IA generativa.
Absci (Nasdaq: ABSI)가 생성 AI를 이용하여 최대 6개의 새로운 암 치료제를 발견하고 개발하기 위해 Memorial Sloan Kettering Cancer Center (MSK)와 협력한다고 발표했습니다. 이번 파트너십은 Absci의 통합 약물 개발™ 플랫폼과 MSK의 저명한 암 연구 전문성을 결합합니다. 협력의 목표는 암 연구를 발전시키고 환자를 위한 새로운 치료법을 개발하는 것입니다.
이번 이니셔티브는 AstraZeneca, Almirall, Merck, NVIDIA와의 파트너십을 포함하여 Absci의 증가하는 연구 및 약물 개발 협력 목록에 추가됩니다. Absci는 또한 생성 AI를 사용하여 설계된 잠재적인 최우수 anti-TL1A 항체인 ABS-101과 같은 자체 약물 후보군을 개발하고 있습니다.
Absci (Nasdaq: ABSI) a annoncé une collaboration avec le Memorial Sloan Kettering Cancer Center (MSK) pour découvrir et développer jusqu'à six nouveaux traitements contre le cancer en utilisant l'IA générative. Ce partenariat combine la plateforme Integrated Drug Creation™ d'Absci avec l'expertise renommée de recherche sur le cancer de MSK. L'objectif de cette collaboration est d'avancer la recherche sur le cancer et de développer de nouvelles thérapies pour les patients.
Cette initiative s'ajoute à la liste croissante des collaborations de recherche et de développement de médicaments d'Absci, y compris des partenariats avec AstraZeneca, Almirall, Merck et NVIDIA. Absci développe également son propre portefeuille de candidats médicamenteux, tel que l'ABS-101, un anticorps anti-TL1A potentiellement de premier ordre conçu grâce à l'IA générative.
Absci (Nasdaq: ABSI) hat eine Zusammenarbeit mit dem Memorial Sloan Kettering Cancer Center (MSK) angekündigt, um bis zu sechs neuartige Krebstherapeutika unter Einsatz von generativer KI zu entdecken und zu entwickeln. Diese Partnerschaft kombiniert Absci's Integrated Drug Creation™-Plattform mit der renommierten Krebsforschungsexpertise von MSK. Das Ziel der Zusammenarbeit ist es, die Krebsforschung voranzutreiben und neue Therapien für Patienten zu entwickeln.
Diese Initiative ergänzt die wachsende Liste von Forschungs- und Entwicklungskooperationen von Absci, darunter Partnerschaften mit AstraZeneca, Almirall, Merck und NVIDIA. Absci entwickelt auch ein eigenes Portfolio an Wirkstoffkandidaten, darunter ABS-101, ein potenziell erstklassiger anti-TL1A-Antikörper, der mit generativer KI entworfen wurde.
- Collaboration with leading cancer research center MSK to develop up to six novel cancer therapeutics
- Expanding roster of research and drug development collaborations with global pharma leaders
- Development of internal drug pipeline, including potential best-in-class anti-TL1A antibody (ABS-101)
- None.
This collaboration between Absci and Memorial Sloan Kettering Cancer Center (MSK) marks a significant step in AI-driven drug discovery for oncology. The partnership leverages Absci's generative AI platform to potentially accelerate the development of up to six novel cancer therapeutics.
The alliance combines MSK's world-class oncology expertise with Absci's cutting-edge AI technology, potentially leading to more efficient and targeted drug discovery. This approach could significantly reduce the time and cost associated with traditional drug development processes, which is important in the competitive oncology market.
For Absci, this collaboration enhances its credibility in the AI-driven drug discovery space and expands its portfolio of high-profile partnerships. It follows recent collaborations with pharmaceutical giants like AstraZeneca and Merck, indicating growing industry confidence in Absci's technology.
This collaboration holds promise for advancing cancer treatment strategies. By integrating MSK's extensive clinical expertise with Absci's AI capabilities, we may see the development of more precise and effective cancer therapies. The potential for six new programs suggests a broad approach, possibly targeting multiple cancer types or pathways.
The use of generative AI in this context could lead to the discovery of novel drug targets or innovative approaches to known targets. This technology might help identify unique protein structures or interactions that traditional methods might overlook, potentially resulting in more effective or less toxic treatments.
However, it's important to note that while AI can accelerate discovery, the path to clinical application remains long and complex. Success will depend on how well the AI-generated insights translate into effective and safe therapies in human trials.
For Absci (NASDAQ: ABSI), this collaboration represents a significant business opportunity. Partnerships with prestigious institutions like MSK can enhance a company's reputation and potentially lead to valuable intellectual property. While financial terms weren't disclosed, such collaborations often involve milestone payments and royalties, which could provide future revenue streams for Absci.
Investors should note Absci's growing list of high-profile partnerships, including AstraZeneca, Almirall and Merck. This trend suggests increasing industry validation of Absci's AI platform, which could positively impact the company's valuation and future deal-making potential.
However, it's important to remember that drug development is a long-term, high-risk process. While AI may accelerate discovery, it doesn't guarantee clinical or commercial success. Investors should balance the potential of these collaborations with the inherent risks in the biotech sector.
The collaboration unites Absci’s Generative AI Drug Creation Platform with leading oncology experts to co-develop up to six novel cancer therapeutics
VANCOUVER, Wash. and NEW YORK, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Today, Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, announced a collaboration with Memorial Sloan Kettering Cancer Center (MSK), a leading cancer treatment and research center, to discover and develop novel therapeutics using generative AI for up to six programs. Under the terms of the collaboration, Absci and MSK’s world-renowned cancer research teams will co-develop therapeutics using Absci’s Integrated Drug Creation™ platform.
“MSK has an incredible record of groundbreaking translational and clinical innovations in oncology,” said Sean McClain, Founder & CEO of Absci. “By combining MSK’s research expertise with our generative AI drug creation platform, we have the potential to unlock critical advances toward treating this devastating disease.”
“At MSK, we are committed to continuous innovation as we strive toward our mission of ending cancer for life, and we expect cancer care AI to play an increasingly important role,” said Gregory Raskin, MD, Senior Vice President of Technology Development at MSK. “We look forward to collaborating with Absci in leveraging the company’s generative AI platform in our ongoing efforts to advance cancer research and develop new therapies for our patients.”
The new collaboration adds to Absci’s roster of research and drug development collaborations designed to develop novel biologics for debilitating diseases. In the last year, Absci has joined forces with global pharma leaders and research institutes, including AstraZeneca and Almirall, alongside existing collaborations with Merck, NVIDIA and others. In addition to drug creation partnerships, Absci continues to develop a pipeline of internal drug candidates, including ABS-101, a potential best-in-class anti-TL1A antibody, designed and optimized using generative AI.
About Absci
Absci is a data-first generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our Integrated Drug Creation™ platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to train, the AI to create, and the wet lab to validate, we can screen billions of cells per week, allowing us to go from AI-designed antibodies to wet lab-validated candidates in as little as six weeks. Absci’s headquarters is in Vancouver, WA, with our AI Research Lab in New York City and an Innovation Center in Zug, Switzerland. Visit www.absci.com and follow us on LinkedIn (@absci), X (Twitter) (@Abscibio), and YouTube.
Absci Forward-Looking Statements
Certain statements in this press release that are not historical facts are considered forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements containing the words “will,” “may,” “pursues,” “anticipates,” “plans,” “believes,” “aims,” “potential,” “forecast,” “estimates,” “extends,” “expects,” and “intends,” or similar expressions. We intend these forward-looking statements, including statements regarding the capabilities of our Integrated Drug Creation platform, our technology development efforts and the application of those efforts, the potential benefits of our partnership with MSK, the success of our partnerships and the ability to generate advancements towards treating disease using generative AI drug creation to accelerate the development of novel candidate therapies, the anticipated value to us under our partnerships, and our internal therapeutic asset programs, the progress, milestones and success of our internal asset programs, including the potential best-in-class profile of our ABS-101 asset program, to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act, and we make this statement for purposes of complying with those safe harbor provisions. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies, and prospects, which are based on the information currently available to us and on assumptions we have made. We can give no assurance that the plans, intentions, expectations, or strategies will be attained or achieved, and furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control, including, without limitation, risks and uncertainties relating to our ability to effectively collaborate on research, drug discovery and development activities with our partners or potential partners, our dependence on third parties to support our internal development programs, including for the manufacture and supply of preclinical and clinical supplies of our product candidates or components thereof, our existing and potential partners’ ability and willingness to pursue the development and commercialization of programs or product candidates under the terms of our partnership agreements, and overall market conditions and regulatory developments that may affect our and our partners’ activities under these agreements, along with those risks set forth in our most recent periodic report filed with the U.S. Securities and Exchange Commission, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the U.S. Securities and Exchange Commission. Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events, or otherwise.
Media Contact
press@absci.com
Investor Contact
investors@absci.com
FAQ
What is the purpose of Absci's collaboration with Memorial Sloan Kettering Cancer Center?
How many potential cancer therapeutics will Absci and MSK develop together?
What is Absci's internal drug candidate ABS-101?
Which other companies has Absci collaborated with for drug development?
